Details of the Drug

General Information of Drug (ID: DM8GFEV)

Drug Name

Atacicept

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 3	[1]
Lupus	4A40	Phase 2	[2]
Multiple sclerosis	8A40	Phase 2	[3]
Rheumatoid arthritis	FA20	Phase 2	[3]
Systemic lupus erythematosus	4A40.0	Phase 2	[4]
------------------------------------------------------------------------------------

Sequence

AMRSCPEEQYWDPLLGTCMSCKTICNHQSQRTCAAFCRSLSCRKEQGKFYDHLLRDCISC
ASICGQHPKQCAYFCENKLRSEPKSSDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
NGKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP
SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
HYTQKSLSLSPGK

Cross-matching ID

DrugBank ID: DB06399
TTD ID: D04YWM

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
A proliferation-inducing ligand (APRIL)	TTOI1RM	TNF13_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72.
2	ClinicalTrials.gov (NCT01972568) Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus. U.S. National Institutes of Health.
3	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)